Skip to main content
SpringerLink
Log in

Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—A retrospective analysis of real-world data

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

In type 2 diabetes patients treated in German primary care practices, the use of dipeptidyl peptidase-4 inhibitor (DPP4i) in combination with metformin was associated with a significant decrease in the risk of developing bone fractures compared to metformin monotherapy.

Introduction

The goal of this study was to analyze the impact of dipeptidyl peptidase-4 inhibitor (DPP4i) use on the risk of bone fracture in patients diagnosed with type 2 diabetes mellitus (T2DM) in Germany.

Methods

Patients with an initial prescription of metformin between 2008 and 2014 from 1262 German general practitioner practices were selected. We matched 4160 DPP4i ever users to never users (1:1) based on age, sex, diabetes duration, body mass index, index year, and physician type. The primary outcome measure was the rate of bone fractures within five years of the start of metformin or DPP-4i therapy. Time-dependent Cox regression models were used to estimate hazard ratios (HRs) for fractures as a function of the DPP4i therapy.

Results

The mean age among the patients was 61.6 years (SD = 11.1 years), 59.6% were men, and 3.1% were followed in diabetologist practices. The mean diabetes duration was 1.5 years (SD = 2.4 years), HbA1c levels were 7.1% in DPP4i users and 6.6% in non-users, and body mass index was 31.5 kg/m2 (SD = 5.0 kg/m2). Within five years of the index date, 6.4% of users and 8.3% of non-users developed bone fractures (log-rank p-value < 0.001). Within five years of the index date, 7.4% of female and 4.7% of male users and 13.3% of female and 8.8% of male non-users were diagnosed with bone fractures (both log-rank p-values < 0.001). The use of DPP4i was associated with a significant decrease in the risk of developing bone fractures (all patients HR = 0.67, 95% CI 0.54–0.84; women HR = 0.72, 95% CI 0.54–0.97; men HR = 0.62, 95% CI 0.44–0.88).

Conclusion

DPP4i use was associated with a decrease in the risk of bone fracture.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Diabetes: facts and figures. Int. Diabetes Fed. 2015. Accessed 3 March 2017. Available at: http://www.idf.org/about-diabetes/facts-figures

  2. Germany. Int. Diabetes Fed. 2015. Accessed 3 March 2017. Available at: http://www.idf.org/membership/eur/germany

  3. Tuominen JT, Impivaara O, Puukka P, Rönnemaa T (1999) Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22:1196–1200

    Article  CAS  PubMed  Google Scholar 

  4. Vestergaard P: Bone metabolism in type 2 diabetes and role of thiazolidinediones. Curr Opin Endocrinol Diabetes Obes 2009, 16:125–131. [doi: 10.1097/MED.0b013e328325d155]

  5. Mamza J, Marlin C, Wang C, Chokkalingam K, Idris I (2016) DPP-4 inhibitor therapy and bone fractures in people with type 2 diabetes—a systematic review and meta-analysis. Diabetes Res Clin Pract 116:288–298. doi:10.1016/j.diabres.2016.04.029

    Article  CAS  PubMed  Google Scholar 

  6. Wallace C, Reiber GE, LeMaster J, Smith DG, Sullivan K, Hayes S, Vath C (2002) Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer. Diabetes Care 25:1983–1986

    Article  PubMed  Google Scholar 

  7. Carnevale V, Romagnoli E, D’Erasmo E (2004) Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196–204. doi:10.1002/dmrr.449

    Article  PubMed  Google Scholar 

  8. Montagnani A, Gonnelli S (2013) Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes Metab 15:784–791. doi:10.1111/dom.12077

    Article  CAS  PubMed  Google Scholar 

  9. Monami M, Dicembrini I, Antenore A, Mannucci E (2011) Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 34:2474–2476. doi:10.2337/dc11-1099

    Article  PubMed  PubMed Central  Google Scholar 

  10. Fu J, Zhu J, Hao Y, Guo C, Zhou Z (2016) Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci Rep 6:29104. doi:10.1038/srep29104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Driessen JHM, van den Bergh JPW, van Onzenoort HAW, Henry RMA, Leufkens HGM, de Vries F (2016) Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture; a retrospective population-based cohort study. Diabetes Obes Metab. doi:10.1111/dom.12843

    PubMed  Google Scholar 

  12. Becher H, Kostev K, Schröder-Bernhardi D (2009) Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47:617–626

    Article  CAS  PubMed  Google Scholar 

  13. Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P (2014) Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 25:2721–2728. doi:10.1007/s00198-014-2810-6

    Article  CAS  Google Scholar 

  14. Jacob L, Dreher M, Kostev K, Hadji P (2016) Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 27:963–969. doi:10.1007/s00198-015-3378-5

    Article  CAS  Google Scholar 

  15. Kyvernitakis I, Kostev K, Nassour T, Thomasius F, Hadji P (2017) The impact of depot medroxyprogesterone acetate on fracture risk: a case–control study from the UK. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 28:291–297. doi:10.1007/s00198-016-3714-4

    Article  CAS  Google Scholar 

  16. Allison PD (2010) Survival analysis using SAS: a practical guide, 2nd edn. SAS Institute, Cary

  17. Majima T, Komatsu Y, Yamada T, Koike Y, Shigemoto M, Takagi C, Hatanaka I, Nakao K (2005) Decreased bone mineral density at the distal radius, but not at the lumbar spine or the femoral neck, in Japanese type 2 diabetic patients. Osteoporos Int 16:907–913. doi:10.1007/s00198-004-1786-z

    Article  CAS  PubMed  Google Scholar 

  18. Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 18:427–444. doi:10.1007/s00198-006-0253-4

    Article  CAS  PubMed  Google Scholar 

  19. Rathmann W, Kostev K (2015) Fracture risk in patients with newly diagnosed type 2 diabetes: a retrospective database analysis in primary care. J Diabetes Complicat 29:766–770. doi:10.1016/j.jdiacomp.2015.05.007

    Article  PubMed  Google Scholar 

  20. Pscherer S, Kostev K, Dippel FW, Rathmann W (2016) Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care. Diabetes Metab Syndr Obes Targets Ther 9:17–23. doi:10.2147/DMSO.S101370

    CAS  Google Scholar 

  21. Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, Arnol V, Sedlinsky C (2010) Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res Off J Am Soc Bone Miner Res 25:211–221. doi:10.1359/jbmr.090732

    Article  CAS  Google Scholar 

  22. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N (2008) The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149:574–579. doi:10.1210/en.2007-1292

    Article  CAS  PubMed  Google Scholar 

  23. Nuche-Berenguer B, Moreno P, Esbrit P, Dapía S, Caeiro JR, Cancelas J, Haro-Mora JJ, Villanueva-Peñacarrillo ML (2009) Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 84:453. doi:10.1007/s00223-009-9220-3

    Article  CAS  PubMed  Google Scholar 

  24. Janssen P, Rotondo A, Mulé F, Tack J (2013) Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther 37:18–36. doi:10.1111/apt.12092

    Article  CAS  PubMed  Google Scholar 

  25. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C (2009) Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 45:833–842. doi:10.1016/j.bone.2009.07.008

    Article  CAS  PubMed  Google Scholar 

  26. Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, Shorr RI, Vinik AI, Odden MC, Park SW et al (2008) Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 31:391–396. doi:10.2337/dc07-1152

    Article  PubMed  Google Scholar 

  27. Kim J-H, Jung M-H, Lee J-M, Son H-S, Cha B-Y, Chang S-A (2012) Diabetic peripheral neuropathy is highly associated with nontraumatic fractures in Korean patients with type 2 diabetes mellitus. Clin Endocrinol 77:51–55. doi:10.1111/j.1365-2265.2011.04222.x

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Epidemiology, IMS Health, Darmstädter Landstraße 108, 60598, Frankfurt am Main, Germany

    S. Dombrowski & K. Kostev

  2. Faculty of Medicine, University of Paris 5, Paris, France

    L. Jacob

Authors
  1. S. Dombrowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Kostev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Kostev.

Ethics declarations

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dombrowski, S., Kostev, K. & Jacob, L. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—A retrospective analysis of real-world data. Osteoporos Int 28, 2421–2428 (2017). https://doi.org/10.1007/s00198-017-4051-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-017-4051-y

Keywords

Search

Navigation